Complement-based Drug Development 2020

Memo

The 2020 meeting is bringing you the latest clinical advancements in complement therapeutics both through physical meeting taking place in Boston and Virtually. With the ongoing COVID-19 pandemic, complement therapies are offering a glimmer of hope for us all. This year you can expect to hear from industry leaders showcasing the next generation of drugs aimed at complement system modulation, longer durations of action, organ-specific delivery and intracellular targeting. The 2020 meeting is bringing you the latest clinical advancements in complement therapeutics. With the ongoing COVID-19 pandemic, . Attend this event to: - Learn how different global leaders are employing state-the-art strategies to manipulate specific areas of the complement cascade within a range of disease indications - Analyze how to translate data from animal models into the human analog - Take advantage of three days of unparalleled networking and come away with the knowledge to overcome your end-to-end challenges from preclinical modelling to streamlining process development - Learn how to leverage translational biomarkers to accelerate development of complement directed therapies - Hear an update from the latest results coming out of the clinic Prices: Conference + 1 Workshop (Industry - On-site): USD 2698.0, Conference Only ( Industry - On-site): USD 2299.0, Conference + 1 Workshop (Vendor - On-site): USD 4198.0, Conference Only (Vendor - On-site): USD 3499.0, Conference + 1 Workshop (Academic - On-site): USD 2248.0, Conference Only (Academic - On-site): USD 1799.0, Conference + 1 Workshop (Industry - Digital- VAT Applied): USD 2064.0, Conference Only (Industry - Digital-VAT Applied): USD 1749.0, Conference + 1 Workshop (Industry - Digital- No VAT Applied): USD 2064.0, Conference Only (Industry - Digital-VAT Applied): USD 1749.0 Speakers: Wynne Weston, Akari Therapeutics, Christopher Campbell, Aurin Biotech, Laura Gault, Alexion, Michele Mercuri, Alexion, Sanjay Keswani, Annexon Biosciences, Thomas Schall, ChemoCentryx, Francesca Granata, Fondazione IRCCS Ca’Granda Ospedale Maggiore Policlinico di Milano, Edward Patz, Grid Therapeutics, Cynthia Lemere, Harvard Medical School, Abhigyan Satyam, Harvard Medical School, Adam Rogers, Hemera Biosciences, Giulio Pasinetti, Icahn School of Medicine at Mount Sinai, Renfeng Guo, InflaRx, Stephen Poor, Novartis Institutes for Biomedical Research, Sha-mei Liao, Novartis Institutes for Biomedical Research, Steve Whitaker, Omeros, Elena Volokhina, Radboud University, Karoline Meagher, Regeneron, Michael Storek, SanofiCamil Sayegh, Verena Aumiller, Silence Therapeutics, Camil Sayegh, UCB Ra Pharma, Joerg Koehl, University of Luebeck, Christian Keller, University of Münster, Julia Koeppe, SUNY Oswego Time: 8:00 am - 6:15 pm